{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-035424","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2025-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.347509+00:00","generated_at":"2026-05-18T05:25:23.503216+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Champions Oncology appoints Robert Brainin as CEO effective Aug 25, 2025","bullets":["Robert Brainin named CEO, effective August 25, 2025; he was a Board member since Feb 2021.","Annual base salary of $500,000; target incentive bonus of 75% of base salary.","Equity awards: 225,000 options (4-year vest) and 475,000 performance-based options.","Ronnie Morris, M.D., transitions to Executive Chairman; Joel Ackerman becomes Director.","Brainin brings 25+ years life sciences/tech experience; most recently CBO at Veracyte."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-035424","json":"https://secwatch.observer/filing/0001628280-25-035424.json","markdown":"https://secwatch.observer/filing/0001628280-25-035424.md","text":"https://secwatch.observer/filing/0001628280-25-035424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828025035424/0001628280-25-035424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828025035424/csbr-20250721.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:25:23.503216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}